Hyderabad, Jan. 28 -- Global pharma major Lupin Limited (Lupin) and Avas Pharmaceuticals SRL (Avas) on Tuesday announced the launch of Lupin's orphan drug NaMuscla(R) (mexiletine) in Italy.
Avas will commercialize NaMuscla(R) for the symptomatic treatment of myotonia in adults with non-dystrophic myotonic (NDM) disorders, the pharma company said in a release.
NaMuscla(R) is the first and only licensed product for this indication.
NDM disorders are a group of rare, inherited neuromuscular disorders which is characterised by the inability to relax muscles following voluntary contraction. NaMuscla(R) reduces myotonia symptoms in people with NDM, resulting in a significant improvement in quality of life and other functional and clinical outc...